Presenters
The University of Chicago Medicine
George Bakris, MD, Hon. DSc, FASN, FAHA
Course Details
The goals of treatment of patients with high cardiovascular (CV) risk includes not just blood pressure (BP)-lowering but importantly, the lowering of CV risk and prevention of adverse CV events. During a symposium featuring Professor George Bakris (Chicago, IL, USA) held during the Philippine Heart Association Annual Convention 2023, Professor Bakris underscored the role of inhibition of the renin-angiotensin system and the clinical trials demonstrating the role of telmisartan in lowering CV risk.
Estimated time of Completion: 29 mins.
CPD Points: 0.5 Point
PRC Program No: PROG-2023-62373
Hypertension control for all Pinoys: Managing HPN across its full spectrum Course Outline
- Epidemiology and Burden of Hypertension
- Control Rates of Hypertension
- PRESYON 4: Hypertension in the Philippines
- The disease spectrum of MA and its role as an indicator of inflammation
- Albuminuria as a Risk Marker for Heart Failure
- Definition of hypertension according to clinic (office), ambulatory and home BP levels
- ACC/AHA Focus on CV risk to determine BP goals
- Both Guidelines Stress Proper Cuffs be Used Selection Criteria for BP Cuff Size for Measurement of BP in Adults
- Approach to Therapy
- Best Proven Nonpharmacologic Interventions for Prevention and Treatment of Hypertension
- Initial Combinations of Medications
- ESC/ESH 2018
- 2020 Philippine Hypertension CPG
- Causes of Poor BP control
- Ratio of Observed to Expected Incremental BP-Lowering Effects of Adding a Drug or Doubling the Dose According to Drug Class
- AHA/ACC 2017
- American Society of Hypertension Evidenced Based Fixed Dose Antihypertensive Combinations
- Does Combining a Beta Blocker with a RAS inhibitor have additive BP Effects?
- Pathophysiology of Hypertension Involves the following systems
- Potential Targets for Therapeutic Intervention
- ARBS are they all created equal?
- Receptor Binding affinity relative to half life
- Efficacy: Telmisartan vs Amlodipine Using 24-h ABPM
- Telmisartan vs Losartan on Trough Ambulatory BP (18-24 Hours Post-Dosing)
- Telmisartan Community Access Trial (MICCAT II)
- The ONTARGET/TRANSCEND Trial Programme: Study Design
- TRANSCEND: Trial Design
- Renal benefits of Telmisartan
- Who should be screened for CKD
- ESPRIT: Telmisartan for hypertension with CKD
- AMADEO: telMisartan (80 mg) vs. losArtan (100 mg) in hypertensive type-2 DiabEtic patients with Overt nephropathy
PC-PH-104961 / July 2023